Orchard Therapeutics Limited   Report issue

For profit Phase 2 Phase 3
Founded: London United Kingdom (2015)
Status: Acquired by Kyowa Kirin (2023)

Organization Overview

First Clinical Trial
2016
NCT02999984
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Orchard Therapeutics | Orchard Therapeutics (Europe) Limited

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Immunologic Deficiency Syndromes (Phase 3)

Leukodystrophy, Metachromatic (Phase 3)

Lysosomal Storage Diseases (Phase 3)

Mucopolysaccharidoses (Phase 2)

Mucopolysaccharidosis III (Phase 2)

Severe Combined Immunodeficiency (Phase 3)

Syndrome (Phase 2)

Wiskott-Aldrich Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 7